MicuRx Pharmaceuticals Approved for STAR Market IPO by CSRC
The China Securities Regulatory Commission (CSRC) has approved the initial public offering (IPO) of Sino-US...
Innovent Biologics’ Pemazyre Becomes First FGFR2 Inhibitor Approved in China
China-based Innovent Biologics Inc. (HKG: 1801) announced that the first prescription has been filled in...
Dizal Pharma’s DZD1516 Receives NMPA Green Light for HER2+ Breast Cancer Trial
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192), spun out from AstraZeneca’s China drug discovery unit...
WuXi XDC Partners with AbTis to Advance ADC Development and Manufacturing
WuXi XDC, a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA (SHA: 603259),...
GenScript Biotech’s Legend Biotech Terminates LB1901 CAR-T Phase I Trial
Hong Kong-based GenScript Biotech Corporation (HKG: 1548) announced that its subsidiary Legend Biotech Corporation (NASDAQ:...
ClouDr Group’s Hong Kong IPO Nets HKD 482 Million with Sanofi as Investor
Hangzhou-based ClouDr Group Ltd (HKG: 9955), a one-stop chronic disease management and smart medical platform,...
Baifu Laser Raises RMB 100 Million in Series A Funding for Optoelectronic Equipment
China-based Nanjing Baifu Laser Technology Co., Ltd reportedly raised close to RMB 100 million (USD...
Oriomics Launches XiaoWeiAn Multi-Tumor Early Screening Product
Hangzhou Ao’rui Biological Technology Co., Ltd (Oriomics) announced the market launch of XiaoWeiAn, a multi-tumor...
Zhaoke Ophthalmology Enrolls First Patient in TAB014 Phase III Study for wAMD
Lee’s Pharmaceutical Holdings Ltd’s (HKG: 0950) former subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622) announced the...
GeneRulor Medical Technology Raises Funds for Gene Editing Diagnostics
China-based gene editing specialist ZhuHai GeneRulor Medical Technology Co., Ltd. reportedly raised “tens of millions”...
Brii Biosciences Launches Anti-COVID-19 Antibody Cocktail in China
China-based Brii Biosciences Ltd (HKG: 2137) announced the commercial launch in China of the anti-COVID-19...
Junshi Biosciences’ PD-1 Inhibitor Tuoyi Under FDA Review for NPC Treatment
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) announced that the Biologics License Application (BLA) for...
I-Mab and MorphoSys License Drugs to HIBio in Global Oncology Deal
China-based I-Mab (NASDAQ: IMAB) detailed a licensing and equity investment deal between its German partner...
Adicon Holdings and Guardant Health Partner on Genomic Profiling in China
China-based Adicon Holdings Limited announced a strategic partnership with U.S. firm Guardant Health, Inc. (NASDAQ:...
BeiGene and InnoRNA Partner on mRNA-LNP Therapeutic Development
China-based biotech firm BeiGene (HKG: 6160, SHA: 688235, NASDAQ: BGNE) announced a strategic partnership with...
PackGene and SineuGene Partner on ALS Gene Therapy Research
China-based PackGene has entered into another partnership with compatriot firm SineuGene. This time, the focus...
China Establishes Leadership Group to Combat Drug-Related Crimes
China’s State Council executive body released a notification regarding the establishment of a leadership group...
Phil Rivers Tech Raises RMB 100 Million for Computational Medicine Push
Beijing-based Phil Rivers Tech, a computational medicine-empowered drug developer, reportedly raised close to RMB 100...
Gan & Lee Pharmaceuticals Doses First Patient in GZR101 Phase I Study
China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced that the first patient has been dosed...
Fosun Pharma’s FS-1502 Gets NMPA Approval for Gastric Cancer Study
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that it has...